A causative role of this elevated signaling pathway leading to the development of cardiovascular defects and CCM lesions was shown by the beneficial effects of pharmacological MEKK3 inhibition or genetic reduction of MEKK3, KLF, or ADAMTS signaling (10–13). The gene discussed is MAP3K3; the disease is cerebral cavernous malformation.